Shares of Iovance Biotherapeutics, a clinical-stage biotechnology company, are on the move after a clinical program update. Investors who are pleased to see the company's oncology candidates getting closer to the finish line pushed the stock 20.4% higher on Wednesday.
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.